SPAC Dynamics Special Purpose to Acquire Senti Bio, A Gene Circuit-Engineered Cell Company

- Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity ("PIPE") financing and from non-redemption agreements -
 

 - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds -

- Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, LifeForce Capital, NEA, Parker Institute for Cancer Immunotherapy, and T. Rowe Price funds -

- Senti Bio uses its proprietary Gene Circuit technology platform to program sense-compute-respond capabilities into cell and gene therapies, with the potential to enhance efficacy, specificity and durability against a broad range of diseases that current therapies are presently unable to address -

- IND filings for lead product candidates SENTI-202 and SENTI-301 anticipated in 2023 -

- Merger expected to be completed during 2Q 2022; combined company expected to be listed on the Nasdaq Capital Market -

- Joint investor recorded presentation to discuss the proposed transaction available today, December 20, at 9:00 a.m.ET -